CN109153704A - 与hiv-1免疫原相关的组合物和方法 - Google Patents

与hiv-1免疫原相关的组合物和方法 Download PDF

Info

Publication number
CN109153704A
CN109153704A CN201780027483.6A CN201780027483A CN109153704A CN 109153704 A CN109153704 A CN 109153704A CN 201780027483 A CN201780027483 A CN 201780027483A CN 109153704 A CN109153704 A CN 109153704A
Authority
CN
China
Prior art keywords
hiv
tripolymer
sequence
albumen
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780027483.6A
Other languages
English (en)
Chinese (zh)
Inventor
莱奥波德·孔
扬·A·威尔逊
纳塔利娅·德瓦尔
安德鲁·B·沃德
丹尼斯·伯顿
何林玲
朱江
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of CN109153704A publication Critical patent/CN109153704A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Nanotechnology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201780027483.6A 2016-05-02 2017-05-01 与hiv-1免疫原相关的组合物和方法 Pending CN109153704A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662330604P 2016-05-02 2016-05-02
US62/330,604 2016-05-02
PCT/US2017/030375 WO2017192434A1 (en) 2016-05-02 2017-05-01 Compositions and methods related to hiv-1 immunogens

Publications (1)

Publication Number Publication Date
CN109153704A true CN109153704A (zh) 2019-01-04

Family

ID=60203504

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780027483.6A Pending CN109153704A (zh) 2016-05-02 2017-05-01 与hiv-1免疫原相关的组合物和方法

Country Status (13)

Country Link
US (5) US10647748B2 (https=)
EP (1) EP3452494A4 (https=)
JP (1) JP7046832B2 (https=)
CN (1) CN109153704A (https=)
AU (2) AU2017259275C1 (https=)
BR (1) BR112018072248A2 (https=)
CA (1) CA3022826A1 (https=)
EA (1) EA201892233A1 (https=)
IL (2) IL299962A (https=)
MX (1) MX2018013455A (https=)
SG (1) SG11201809387QA (https=)
WO (1) WO2017192434A1 (https=)
ZA (1) ZA201807216B (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111647078A (zh) * 2020-06-22 2020-09-11 中国医学科学院医学生物学研究所 一种抗hiv的单克隆抗体及其制备方法和应用
CN114478796A (zh) * 2020-11-12 2022-05-13 厦门大学 经改造的人免疫缺陷病毒膜蛋白及其应用
CN116769053A (zh) * 2023-05-26 2023-09-19 华中农业大学 重组AaLS-BPP融合肽、制备方法及应用
CN121293297A (zh) * 2025-12-04 2026-01-09 广州千扬生物医药技术有限公司 一种hiv纳米颗粒疫苗

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11572389B2 (en) * 2017-01-27 2023-02-07 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine compositions of herpesvirus envelope protein combinations to induce immune response
CN112469661B (zh) * 2018-06-13 2024-04-26 斯克里普斯研究学院 具有新结构组分的纳米粒疫苗
WO2020117760A1 (en) * 2018-12-03 2020-06-11 Duke University Purification method for recombinant proteins and nanoparticles
AU2020323462A1 (en) * 2019-07-26 2022-03-10 The Scripps Research Institute Engineered HCV E2 immunogens and related vaccine compositions
EP4051318A4 (en) * 2019-10-29 2023-10-11 International AIDS Vaccine Initiative ENGINEERED ANTI-ENV HIV ANTIBODIES
JP7170942B1 (ja) * 2019-11-07 2022-11-14 ヤンセン ファッシンズ アンド プリベンション ベーフェー タンパク質精製
US10906944B2 (en) 2020-06-29 2021-02-02 The Scripps Research Institute Stabilized coronavirus spike (S) protein immunogens and related vaccines

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063331A2 (en) * 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU698962B2 (en) 1993-09-14 1998-11-12 Epimmune, Inc. Alteration of immune response using pan DR-binding peptides
US7550143B2 (en) 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
JP2011502521A (ja) * 2007-11-12 2011-01-27 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド Ｈｉｖ−１外被糖タンパク質オリゴマー及び使用方法
RU2540871C2 (ru) 2008-02-01 2015-02-10 Альфа-О Пептидес Аг Самоорганизующиеся пептидные наночастицы, полезные в качестве вакцин
EP2765138B1 (en) * 2012-11-05 2018-01-10 International Aids Vaccine Initiative HIV-1 envelope glycoprotein
AP2015008634A0 (en) 2013-01-07 2015-07-31 Beth Israel Hospital Stabilized human immunodeficiency virus 'hiv' env elope 'env' trimer vaccines and methods of using same
WO2016037154A1 (en) * 2014-09-04 2016-03-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant hiv-1 envelope proteins and their use
US10501733B2 (en) 2015-02-27 2019-12-10 University Of Washington Polypeptide assemblies and methods for the production thereof
AR109528A1 (es) * 2016-09-15 2018-12-19 Janssen Vaccines & Prevention Bv Mutaciones estabilizantes de trímeros de proteínas de la envoltura del vih

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063331A2 (en) * 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
IVELIN S. GEORGLEV ET AL.: "Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env", 《JOURNAL OF VIROLOGY》 *
SLIEPEN ET AL.: "Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity", 《RETROVIROLOGY》 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111647078A (zh) * 2020-06-22 2020-09-11 中国医学科学院医学生物学研究所 一种抗hiv的单克隆抗体及其制备方法和应用
CN111647078B (zh) * 2020-06-22 2022-04-26 中国医学科学院医学生物学研究所 一种抗hiv的单克隆抗体及其制备方法和应用
CN114478796A (zh) * 2020-11-12 2022-05-13 厦门大学 经改造的人免疫缺陷病毒膜蛋白及其应用
WO2022100703A1 (zh) * 2020-11-12 2022-05-19 厦门大学 经改造的人免疫缺陷病毒膜蛋白及其应用
CN116769053A (zh) * 2023-05-26 2023-09-19 华中农业大学 重组AaLS-BPP融合肽、制备方法及应用
CN116769053B (zh) * 2023-05-26 2023-12-15 华中农业大学 重组AaLS-BPP融合肽、制备方法及应用
CN121293297A (zh) * 2025-12-04 2026-01-09 广州千扬生物医药技术有限公司 一种hiv纳米颗粒疫苗

Also Published As

Publication number Publication date
AU2017259275A1 (en) 2018-11-15
IL262582B2 (en) 2023-06-01
JP7046832B2 (ja) 2022-04-04
IL299962A (en) 2023-03-01
US20240083954A1 (en) 2024-03-14
MX2018013455A (es) 2019-02-28
US20190048043A1 (en) 2019-02-14
US20200165303A1 (en) 2020-05-28
SG11201809387QA (en) 2018-11-29
WO2017192434A1 (en) 2017-11-09
ZA201807216B (en) 2020-01-29
US11767347B2 (en) 2023-09-26
IL262582A (en) 2018-12-31
EA201892233A1 (ru) 2019-07-31
US20250122247A1 (en) 2025-04-17
US20220098244A1 (en) 2022-03-31
EP3452494A1 (en) 2019-03-13
US11236134B2 (en) 2022-02-01
BR112018072248A2 (pt) 2019-02-12
US10647748B2 (en) 2020-05-12
JP2019522626A (ja) 2019-08-15
CA3022826A1 (en) 2017-11-09
AU2021221582A1 (en) 2021-10-07
AU2017259275C1 (en) 2022-01-27
EP3452494A4 (en) 2020-01-01
AU2021221582B2 (en) 2022-10-20
AU2017259275B2 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
CN109153704A (zh) 与hiv-1免疫原相关的组合物和方法
Hoxie Toward an antibody-based HIV-1 vaccine
Do Kwon et al. Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env
Georgiev et al. Two-component ferritin nanoparticles for multimerization of diverse trimeric antigens
de Taeye et al. HIV-1 envelope trimer design and immunization strategies to induce broadly neutralizing antibodies
Chuang et al. Structure-based design of a soluble prefusion-closed HIV-1 Env trimer with reduced CD4 affinity and improved immunogenicity
US12458691B2 (en) HIV-1 ENV fusion peptide immunogens and their use
Kong et al. Antigenicity and immunogenicity in HIV-1 antibody-based vaccine design
EP3189067A1 (en) Recombinant hiv-1 envelope proteins and their use
US11452771B2 (en) Scaffolded HIV-1 Env GP140 trimer immunogen
US10058604B2 (en) Soluble HIV-1 envelope glycoprotein trimers
Chuang et al. Development of a 3Mut-apex-stabilized envelope trimer that expands HIV-1 neutralization breadth when used to boost fusion peptide-directed vaccine-elicited responses
Shivatare et al. Immunogenicity evaluation of N-glycans recognized by HIV broadly neutralizing antibodies
US20250059238A1 (en) Recombinant hiv env polypeptides and their uses
EA041182B1 (ru) Композиции и способы, связанные с иммуногенами вич-1
Singh et al. Immunogenicity and Structure of stabilized HIV-1 Clade-C Env from pediatric Elite-neutralizer complexed with autologous bNAb
EA050067B1 (ru) ПОЛИНУКЛЕОТИД, КОДИРУЮЩИЙ МОНОМЕР МОДИФИЦИРОВАННОГО ТРИМЕРНОГО БЕЛКА gp140 ОБОЛОЧКИ ВИЧ-1, СОДЕРЖАЩИЕ ЕГО ВЕКТОР И КЛЕТКА И СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ИНФЕКЦИИ ВИЧ-1
Restrepo Computational Vaccine Design of Class I Fusion Proteins
Gonzalez Computational Vaccine Design of Class I Fusion Proteins

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination